Date Log
Submitted
August 15, 2020
Published
August 15, 2020
Gastroretentive drug delivery system: A review
Corresponding Author(s) : Bhavana. Salunke
ijamscr@gmail.com
International Journal of Allied Medical Sciences and Clinical Research,
Vol. 8 No. 2 (2020): 2020 Volume 8- Issue -2
Abstract
GRDDs are an approach to prolong gastric residence time, there by targeting site-specific drug release in the upper GIT for local or systemic effect. Gastro retentive dosage forms (GRDFs) are being used from a very long time to improve therapy with several important drugs. GRDFs greatly improves the pharmacotherapy of stomach by releasing the drug locally and thus results into high concentration of drug at the gastric mucosa which can be sustained over a longer duration of time. GRDFs enable prolonged and continuous release of the drug to the upper part of Gastro intestinal tract (GIT) and this significantly extend the duration of drug release and improve bioavailability of drugs that have narrow therapeutic window, by this way they prolong dosing interval and increase compliance of the patient. The purpose of this paper is to briefly describe the gastro retentive drug delivery (GRDD), factors related to GRDD, its advantages disadvantages, and emphasis is given over its significance over conventional form of drug deliveries
Keywords
Gastric residence time
Gastro retention
Hydro dynamically balanced system
Effervescent
Non- effervescent
Bhavana. Salunke. (2020). Gastroretentive drug delivery system: A review. International Journal of Allied Medical Sciences and Clinical Research, 8(2), 299–304. https://doi.org/10.61096/ijamscr.v8.iss2.2020.299-304
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
References
-
[1]. Ali J, Arora S, Khar RK, Floating drug delivery system: A review. AAPS Pharma SciTech. 06(03), 2001, E372-E390.
[2]. Amit KN, Ruma M, Biswarup D. Gastro retentive drug delivery system; a review. Asian journal of pharmaceutical and clinical research. 3(1), 2010, 2-10.
[3]. Bardonnet PL, Faivre V, Pugh WJ. Piffaretti JC, Falson F. Gastro retentive dosage forms; overview and special case of helicobacter pyroli. J. control. Release. 111, 2006, 1-18.
[4]. Cadwell LJ, Gardner CR, Cargill RC. Drug delivery device which can be retained in the stomach for a controlled period of time. US4735804, 1998.
[5]. Cadwell LJ, Gardner CR, Cargill RC. Drug delivery device which can be retained in the stomach for a controlled period of time. US4758436, 1988.
[6]. Cadwell LJ, Gardner CR, Cargill RC. Drug delivery device which can be retained in the stomach for a controlled period of time. US Patent 4735804, 1988.
[7]. Lee TW, Robinson JR. Remington’s the science and Practice of Pharmacy, Lippincott Williams & Wilkings; Philadelphia: 20, 2000.
[8]. Chen YC, Ho H, Lee TY, Sheu MT. Physical characterizations and sustained release profiling of gastroretentive drug delivery system with improved floating and swelling capabilities. International Journal of Pharmaceutics. 44, 2013, 162-169.
[9]. Oth M, Franze M, Timmermans J, Moes A, The bilayer floating capsule: a stomach directed drug delivery system for misoprostol. Pharm Res 9, 1992, 298-302.
[10]. Timmermans J, Gasnsbeka BV, Moes A. Accessing by gamma scintigraphy the in vivo buoyancy of dosage form having known size and floating force profiles as a function of time. Pharm Tech, 1, 1989, 42-51.
[11]. Kagan L, Hoffman A, Systems for regions elective drug delivery in gastro intestinal tract: biopharmaceutical considerations. Expert Opinion. Drug Delivery. 5, 2008, 681–692.
[12]. Pawar VK, Kansal S, Asthana S & Chourasia MK. Industrial Perspective of Gastro retentive Drug Delivery System: Physiochemical, Biopharmaceutical, Technological and regulatory considerations. Expert opinion on drug delivery. 9, 2012, 551.
[13]. Li S, Lin S, Daggy BP, Mirchandani HL, Chien YW. Effect of HPMC and Carbopol on the release and floating properties of gastric floating drug delivery system using factorial design. Int J Pharm, 253, 2003, 13-22.
[14]. Singh B.N, Kim K.H. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release. 63, 2000, 235–259.
[15]. Vyas SP, Khar RK. Controlled drug delivery: concept and advances. Vallabh prakashan: Delhi; 2002.
[16]. Chawla G, Gupta P, Koradia V, Bansal AK. Gastro retention: A Means to address regional variability in intestinal drug absorption. Pharm Tech, 27, 2003, 250-268.
[17]. Muller Lissner SA, Blum AL. The effect of specific gravity and eating on gastric emptying of slow release capsules. New Engl J Med, 304, 1981, 1365-1366. [18]. 18 Singh BN, Kim KH. Floating drug delivery system: An approach to the controlled drug delivery via gastric retention. J Control Release, 63, 2000, 235-259.
[19]. Shah SH, Patel JK, Patel NV. Stomach specific floating drug delivery system: A review. Int J Pharm Res, 1(3), 2009, 623-633.
[20]. Devereux JE, Newton JM, Short MB. The influence of density on the gastrointestinal transit of pellets. J Pharm Pharmacol, 42(7), 1990, 500-501.
[21]. Klausner EA, Eyal S, Lavy E .Novel levodopa gastro retentive dosage form: in-vivo evaluation in dogs. Journal of Control Release. 88(1), 2003, 117-126.
[22]. Soni RP, Patel AV and Patel RB: Gastro retentive drug delivery systems: A review. International Journal of Pharma World Research, 2, 2011, 1-24.
[23]. Oth M, Franz M, Timmermans J, Moes AJ. The bilayer floating capsule: A stomach directed drug delivery system for misoprostol. Pharm Res, 9, 1992, 298.
[24]. Mishra A and Gupta P: Gastro retentive drug delivery system: A review. International Journal of Drug Development and Research, 4, 2012, 28-39.
[25]. Kumar MK, Shah MH, Ketkar A, Madhik KR, Paradkar A. Effect of drug solubility and different excipients on floating behaviour and release from glyceryl monooleate matrices. Int J Pharm. 272, 2004, 151.
[26]. Harrigan RM: Drug delivery device for preventing contact of un dissolved drug with the stomach lining. US Patent 4055178, 1977.
[27]. Dave BS, Amin AF, Patel MM. Gastro retentive drug delivery system of Ranitidine Hydrochloride: Formulation and In Vitro Evaluation. American Association of Pharmaceutical Scientists Pharm Sci Tech. 2004, 5-11.
[28]. Sharma N, Agarwal D, Gupta M and Khinchi M: A comprehensive review on floating drug delivery system. International Journal of Research in Pharmaceutical and Biomedical sciences, 2, 2011, 428-441.
[29]. Yellanki SK, Singh J, Syed JA et al. Design and characterization of Amoxicillin trihydrate muco adhesive microspheres for prolonged gastric retention. International Journal of Pharmaceutical Sciences and Drug Research. 2, 2010, 112.
[30]. Asane GS. Muco adhesive gastrointestinal drug delivery system: An overview. 2007; www.pharmainfo.net.
References
[1]. Ali J, Arora S, Khar RK, Floating drug delivery system: A review. AAPS Pharma SciTech. 06(03), 2001, E372-E390.
[2]. Amit KN, Ruma M, Biswarup D. Gastro retentive drug delivery system; a review. Asian journal of pharmaceutical and clinical research. 3(1), 2010, 2-10.
[3]. Bardonnet PL, Faivre V, Pugh WJ. Piffaretti JC, Falson F. Gastro retentive dosage forms; overview and special case of helicobacter pyroli. J. control. Release. 111, 2006, 1-18.
[4]. Cadwell LJ, Gardner CR, Cargill RC. Drug delivery device which can be retained in the stomach for a controlled period of time. US4735804, 1998.
[5]. Cadwell LJ, Gardner CR, Cargill RC. Drug delivery device which can be retained in the stomach for a controlled period of time. US4758436, 1988.
[6]. Cadwell LJ, Gardner CR, Cargill RC. Drug delivery device which can be retained in the stomach for a controlled period of time. US Patent 4735804, 1988.
[7]. Lee TW, Robinson JR. Remington’s the science and Practice of Pharmacy, Lippincott Williams & Wilkings; Philadelphia: 20, 2000.
[8]. Chen YC, Ho H, Lee TY, Sheu MT. Physical characterizations and sustained release profiling of gastroretentive drug delivery system with improved floating and swelling capabilities. International Journal of Pharmaceutics. 44, 2013, 162-169.
[9]. Oth M, Franze M, Timmermans J, Moes A, The bilayer floating capsule: a stomach directed drug delivery system for misoprostol. Pharm Res 9, 1992, 298-302.
[10]. Timmermans J, Gasnsbeka BV, Moes A. Accessing by gamma scintigraphy the in vivo buoyancy of dosage form having known size and floating force profiles as a function of time. Pharm Tech, 1, 1989, 42-51.
[11]. Kagan L, Hoffman A, Systems for regions elective drug delivery in gastro intestinal tract: biopharmaceutical considerations. Expert Opinion. Drug Delivery. 5, 2008, 681–692.
[12]. Pawar VK, Kansal S, Asthana S & Chourasia MK. Industrial Perspective of Gastro retentive Drug Delivery System: Physiochemical, Biopharmaceutical, Technological and regulatory considerations. Expert opinion on drug delivery. 9, 2012, 551.
[13]. Li S, Lin S, Daggy BP, Mirchandani HL, Chien YW. Effect of HPMC and Carbopol on the release and floating properties of gastric floating drug delivery system using factorial design. Int J Pharm, 253, 2003, 13-22.
[14]. Singh B.N, Kim K.H. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release. 63, 2000, 235–259.
[15]. Vyas SP, Khar RK. Controlled drug delivery: concept and advances. Vallabh prakashan: Delhi; 2002.
[16]. Chawla G, Gupta P, Koradia V, Bansal AK. Gastro retention: A Means to address regional variability in intestinal drug absorption. Pharm Tech, 27, 2003, 250-268.
[17]. Muller Lissner SA, Blum AL. The effect of specific gravity and eating on gastric emptying of slow release capsules. New Engl J Med, 304, 1981, 1365-1366. [18]. 18 Singh BN, Kim KH. Floating drug delivery system: An approach to the controlled drug delivery via gastric retention. J Control Release, 63, 2000, 235-259.
[19]. Shah SH, Patel JK, Patel NV. Stomach specific floating drug delivery system: A review. Int J Pharm Res, 1(3), 2009, 623-633.
[20]. Devereux JE, Newton JM, Short MB. The influence of density on the gastrointestinal transit of pellets. J Pharm Pharmacol, 42(7), 1990, 500-501.
[21]. Klausner EA, Eyal S, Lavy E .Novel levodopa gastro retentive dosage form: in-vivo evaluation in dogs. Journal of Control Release. 88(1), 2003, 117-126.
[22]. Soni RP, Patel AV and Patel RB: Gastro retentive drug delivery systems: A review. International Journal of Pharma World Research, 2, 2011, 1-24.
[23]. Oth M, Franz M, Timmermans J, Moes AJ. The bilayer floating capsule: A stomach directed drug delivery system for misoprostol. Pharm Res, 9, 1992, 298.
[24]. Mishra A and Gupta P: Gastro retentive drug delivery system: A review. International Journal of Drug Development and Research, 4, 2012, 28-39.
[25]. Kumar MK, Shah MH, Ketkar A, Madhik KR, Paradkar A. Effect of drug solubility and different excipients on floating behaviour and release from glyceryl monooleate matrices. Int J Pharm. 272, 2004, 151.
[26]. Harrigan RM: Drug delivery device for preventing contact of un dissolved drug with the stomach lining. US Patent 4055178, 1977.
[27]. Dave BS, Amin AF, Patel MM. Gastro retentive drug delivery system of Ranitidine Hydrochloride: Formulation and In Vitro Evaluation. American Association of Pharmaceutical Scientists Pharm Sci Tech. 2004, 5-11.
[28]. Sharma N, Agarwal D, Gupta M and Khinchi M: A comprehensive review on floating drug delivery system. International Journal of Research in Pharmaceutical and Biomedical sciences, 2, 2011, 428-441.
[29]. Yellanki SK, Singh J, Syed JA et al. Design and characterization of Amoxicillin trihydrate muco adhesive microspheres for prolonged gastric retention. International Journal of Pharmaceutical Sciences and Drug Research. 2, 2010, 112.
[30]. Asane GS. Muco adhesive gastrointestinal drug delivery system: An overview. 2007; www.pharmainfo.net.
[2]. Amit KN, Ruma M, Biswarup D. Gastro retentive drug delivery system; a review. Asian journal of pharmaceutical and clinical research. 3(1), 2010, 2-10.
[3]. Bardonnet PL, Faivre V, Pugh WJ. Piffaretti JC, Falson F. Gastro retentive dosage forms; overview and special case of helicobacter pyroli. J. control. Release. 111, 2006, 1-18.
[4]. Cadwell LJ, Gardner CR, Cargill RC. Drug delivery device which can be retained in the stomach for a controlled period of time. US4735804, 1998.
[5]. Cadwell LJ, Gardner CR, Cargill RC. Drug delivery device which can be retained in the stomach for a controlled period of time. US4758436, 1988.
[6]. Cadwell LJ, Gardner CR, Cargill RC. Drug delivery device which can be retained in the stomach for a controlled period of time. US Patent 4735804, 1988.
[7]. Lee TW, Robinson JR. Remington’s the science and Practice of Pharmacy, Lippincott Williams & Wilkings; Philadelphia: 20, 2000.
[8]. Chen YC, Ho H, Lee TY, Sheu MT. Physical characterizations and sustained release profiling of gastroretentive drug delivery system with improved floating and swelling capabilities. International Journal of Pharmaceutics. 44, 2013, 162-169.
[9]. Oth M, Franze M, Timmermans J, Moes A, The bilayer floating capsule: a stomach directed drug delivery system for misoprostol. Pharm Res 9, 1992, 298-302.
[10]. Timmermans J, Gasnsbeka BV, Moes A. Accessing by gamma scintigraphy the in vivo buoyancy of dosage form having known size and floating force profiles as a function of time. Pharm Tech, 1, 1989, 42-51.
[11]. Kagan L, Hoffman A, Systems for regions elective drug delivery in gastro intestinal tract: biopharmaceutical considerations. Expert Opinion. Drug Delivery. 5, 2008, 681–692.
[12]. Pawar VK, Kansal S, Asthana S & Chourasia MK. Industrial Perspective of Gastro retentive Drug Delivery System: Physiochemical, Biopharmaceutical, Technological and regulatory considerations. Expert opinion on drug delivery. 9, 2012, 551.
[13]. Li S, Lin S, Daggy BP, Mirchandani HL, Chien YW. Effect of HPMC and Carbopol on the release and floating properties of gastric floating drug delivery system using factorial design. Int J Pharm, 253, 2003, 13-22.
[14]. Singh B.N, Kim K.H. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release. 63, 2000, 235–259.
[15]. Vyas SP, Khar RK. Controlled drug delivery: concept and advances. Vallabh prakashan: Delhi; 2002.
[16]. Chawla G, Gupta P, Koradia V, Bansal AK. Gastro retention: A Means to address regional variability in intestinal drug absorption. Pharm Tech, 27, 2003, 250-268.
[17]. Muller Lissner SA, Blum AL. The effect of specific gravity and eating on gastric emptying of slow release capsules. New Engl J Med, 304, 1981, 1365-1366. [18]. 18 Singh BN, Kim KH. Floating drug delivery system: An approach to the controlled drug delivery via gastric retention. J Control Release, 63, 2000, 235-259.
[19]. Shah SH, Patel JK, Patel NV. Stomach specific floating drug delivery system: A review. Int J Pharm Res, 1(3), 2009, 623-633.
[20]. Devereux JE, Newton JM, Short MB. The influence of density on the gastrointestinal transit of pellets. J Pharm Pharmacol, 42(7), 1990, 500-501.
[21]. Klausner EA, Eyal S, Lavy E .Novel levodopa gastro retentive dosage form: in-vivo evaluation in dogs. Journal of Control Release. 88(1), 2003, 117-126.
[22]. Soni RP, Patel AV and Patel RB: Gastro retentive drug delivery systems: A review. International Journal of Pharma World Research, 2, 2011, 1-24.
[23]. Oth M, Franz M, Timmermans J, Moes AJ. The bilayer floating capsule: A stomach directed drug delivery system for misoprostol. Pharm Res, 9, 1992, 298.
[24]. Mishra A and Gupta P: Gastro retentive drug delivery system: A review. International Journal of Drug Development and Research, 4, 2012, 28-39.
[25]. Kumar MK, Shah MH, Ketkar A, Madhik KR, Paradkar A. Effect of drug solubility and different excipients on floating behaviour and release from glyceryl monooleate matrices. Int J Pharm. 272, 2004, 151.
[26]. Harrigan RM: Drug delivery device for preventing contact of un dissolved drug with the stomach lining. US Patent 4055178, 1977.
[27]. Dave BS, Amin AF, Patel MM. Gastro retentive drug delivery system of Ranitidine Hydrochloride: Formulation and In Vitro Evaluation. American Association of Pharmaceutical Scientists Pharm Sci Tech. 2004, 5-11.
[28]. Sharma N, Agarwal D, Gupta M and Khinchi M: A comprehensive review on floating drug delivery system. International Journal of Research in Pharmaceutical and Biomedical sciences, 2, 2011, 428-441.
[29]. Yellanki SK, Singh J, Syed JA et al. Design and characterization of Amoxicillin trihydrate muco adhesive microspheres for prolonged gastric retention. International Journal of Pharmaceutical Sciences and Drug Research. 2, 2010, 112.
[30]. Asane GS. Muco adhesive gastrointestinal drug delivery system: An overview. 2007; www.pharmainfo.net.
